Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant Charcot-Marie-Tooth disease type 2F (CMT2F) is a form of axonal Charcot-Marie-Tooth disease, a peripheral sensorimotor neuropathy. CMT2F is characterized by symmetric weakness primarily occurring in the lower limbs (distal muscles in a majority of cases) and reaching the arms only after 5 to 10 years, occasional and predominantly distal sensory loss and reduced tendon reflexes. CMT2F presents with gait anomaly between the 1st and 6th decade and early onset is generally associated to a more severe phenotype which may include foot drop.
Features include always present findings: Distal muscle weakness; and very common findings: Steppage gait, Pes cavus, Upper limb amyotrophy, and Areflexia of lower limbs and others. 24 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Arms and legs | 8 | Claw hand deformity, Foot dorsiflexor weakness, Hyporeflexia of upper limbs |
Brain and nerves | 7 | Steppage gait, Fasciculations, Chronic axonal neuropathy |
Muscles | 7 | Muscle spasm, Distal muscle weakness, Fasciculations |
HSPB1 encodes heat shock protein family B (small) member 1 (205 aa). Small heat shock protein which functions as a molecular chaperone probably maintaining denatured proteins in a folding-competent state. Plays a role in stress resistance and actin organization. Highest expression in Esophagus Mucosa (4,134 TPM) and Artery Aorta (3,780 TPM).
Charcot-Marie-Tooth disease axonal type 2F is caused by mutations in the HSPB1 gene on chromosome 7.
The HSPB1 protein participates in HSF1-mediated gene expression pathway.
HSPB1 is classified as a druggable target (Druggable Genome category) with score 4.4.
Genetic testing for HSPB1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 14 very common features, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Charcot-Marie-Tooth disease axonal type 2F.
4 publications have been identified in PubMed for Charcot-Marie-Tooth disease axonal type 2F. Research spans Review / Meta-Analysis (50%), Case Report / Case Series (25%), and Basic Science / Preclinical (25%).
Pan X (2026). [PMID: 41677634](https://pubmed.ncbi.nlm.nih.gov/41677634/). *Cells*. [Review / Meta-Analysis]
Lei Y (2025). [PMID: 41158643](https://pubmed.ncbi.nlm.nih.gov/41158643/). *Degenerative neurological and neuromuscular disease*. [Case Report / Case Series]
Sisto A (2025). [PMID: 39698979](https://pubmed.ncbi.nlm.nih.gov/39698979/). *Autophagy*. [Basic Science / Preclinical]
Tazir M (2024). [PMID: 38702287](https://pubmed.ncbi.nlm.nih.gov/38702287/). *Revue neurologique*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 6:20 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease axonal type 2F